PMID- 21800290
OWN - NLM
STAT- MEDLINE
DCOM- 20120416
LR  - 20151119
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 118
IP  - 4
DP  - 2012 Feb 15
TI  - Breast cancers presenting luminal B subtype features show higher discordant human 
      epidermal growth factor receptor 2 results between immunohistochemistry and 
      fluorescence in situ hybridization.
PG  - 914-23
LID - 10.1002/cncr.26406 [doi]
AB  - BACKGROUND: The aims of this study were to compare human epidermal growth factor 
      receptor 2 (HER2) results between immunohistochemistry (IHC) and fluorescence in 
      situ hybridization (FISH), and to investigate the clinicopathological 
      characteristics and outcomes according to their results. METHODS: Using 
      consecutive tissue microarrays, IHC and FISH were performed as guidelines in 950 
      invasive breast cancers treated between November 1999 and August 2005. 
      Characteristics and outcomes were retrospectively analyzed using a chi-square 
      test, the Kaplan-Meier method, and Cox's model. RESULTS: FISH-positivity was 
      observed in 2.6%, 4.8%, 28.1%, and 93.8% of IHC 0, 1+, 2+, and 3+, respectively, 
      and the concordance rate between the 2 assays was 95.5%. IHC-positive or 
      FISH-positive cases were associated with poorer differentiation, negative 
      expression of hormone receptors, and higher proliferative index. Among 
      IHC-equivocal or IHC-negative patients, positive FISH was negatively associated 
      with survival in univariate and multivariate analyses. Among IHC-negative 
      patients, tumors showing luminal B subtype features such as estrogen receptor 
      (ER)-positive, grade II/III, and high Ki-67 presented discordantly high 
      FISH-positivity. Among IHC-positive cases, FISH was not related to outcomes. 
      CONCLUSIONS: The result of FISH is significantly related to prognosis of patients 
      with IHC-negative or IHC-equivocal result. Therefore, FISH should be performed in 
      IHC-equivocal cases. FISH assay might be considered for a selected group of 
      patients with IHC-negative tumors showing luminal B subtype features of 
      ER-positive, grade II/III, and high Ki-67 expression.
CI  - Copyright (c) 2011 American Cancer Society.
FAU - Park, Seho
AU  - Park S
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
FAU - Park, Hyung Seok
AU  - Park HS
FAU - Koo, Ja Seung
AU  - Koo JS
FAU - Yang, Woo Ick
AU  - Yang WI
FAU - Kim, Seung Il
AU  - Kim SI
FAU - Park, Byeong-Woo
AU  - Park BW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110728
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/*metabolism
MH  - Breast Neoplasms/*metabolism/mortality/*pathology
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - Chi-Square Distribution
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2011/07/30 06:00
MHDA- 2012/04/17 06:00
CRDT- 2011/07/30 06:00
PHST- 2010/12/03 00:00 [received]
PHST- 2011/03/16 00:00 [revised]
PHST- 2011/06/08 00:00 [accepted]
PHST- 2011/07/30 06:00 [entrez]
PHST- 2011/07/30 06:00 [pubmed]
PHST- 2012/04/17 06:00 [medline]
AID - 10.1002/cncr.26406 [doi]
PST - ppublish
SO  - Cancer. 2012 Feb 15;118(4):914-23. doi: 10.1002/cncr.26406. Epub 2011 Jul 28.